

The 2021-2026 World Outlook for Coronary Vasodilator Pharmaceuticals

https://marketpublishers.com/r/2300426A6ABEN.html

Date: November 2019 Pages: 300 Price: US\$ 995.00 (Single User License) ID: 2300426A6ABEN

Abstracts

This study covers the world outlook for coronary vasodilator pharmaceuticals across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. This study does not report actual sales data (which are simply unavailable, in a comparable or consistent manner in virtually all of the countries of the world). This study gives, however, my estimates for the worldwide latent demand, or the P.I.E., for coronary vasodilator pharmaceuticals. It also shows how the P.I.E. is divided across the world's regional and national markets. For each country, I also show my estimates of how the P.I.E. grows over time (positive or negative growth). In order to make these estimates, a multi-stage methodology was employed that is often taught in courses on international strategic planning at graduate schools of business.



Contents

1 INTRODUCTION

- 1.1 OVERVIEW
- 1.2 WHAT IS LATENT DEMAND AND THE P.I.E.?
- 1.3 THE METHODOLOGY
- 1.4 FREQUENTLY ASKED QUESTIONS (FAQ)

2 SUMMARY OF FINDINGS

2.1 THE WORLDWIDE MARKET POTENTIAL

3 AFRICA

3.1 EXECUTIVE SUMMARY 3.2 ALGERIA 3.3 ANGOLA 3.4 BENIN 3.5 BOTSWANA 3.6 BURKINA FASO 3.7 BURUNDI 3.8 CAMEROON 3.9 CAPE VERDE **3.10 CENTRAL AFRICAN REPUBLIC** 3.11 CHAD 3.12 COMOROS 3.13 CONGO (FORMERLY ZAIRE) 3.14 COTE D'IVOIRE 3.15 DJIBOUTI 3.16 EGYPT 3.17 EQUATORIAL GUINEA 3.18 ERITREA 3.19 ETHIOPIA 3.20 GABON 3.21 GHANA **3.22 GUINEA** 3.23 GUINEA-BISSAU **3.24 KENYA**

The 2021-2026 World Outlook for Coronary Vasodilator Pharmaceuticals



3.25 LESOTHO 3.26 LIBERIA 3.27 LIBYA 3.28 MADAGASCAR **3.29 MALAWI** 3.30 MALI 3.31 MAURITANIA 3.32 MAURITIUS 3.34 MOROCCO 3.35 MOZAMBIQUE 3.36 NAMIBIA **3.37 NIGER** 3.38 NIGERIA 3.39 REPUBLIC OF CONGO 3.40 RWANDA 3.41 SAO TOME E PRINCIPE 3.42 SENEGAL 3.43 SIERRA LEONE 3.44 SOMALIA 3.45 SOUTH AFRICA 3.46 SOUTH SUDAN 3.47 ST. HELENA 3.48 SUDAN 3.49 SWAZILAND 3.50 TANZANIA 3.51 THE GAMBIA 3.52 TOGO 3.53 TUNISIA 3.54 UGANDA 3.55 WESTERN SAHARA 3.56 ZAMBIA 3.57 ZIMBABWE

4 ASIA

4.1 EXECUTIVE SUMMARY4.2 BANGLADESH4.3 BHUTAN4.4 BRUNEI



4.5 BURMA

4.6 CAMBODIA

- 4.7 CHINA
- 4.8 HONG KONG
- **4.9 INDIA**
- 4.10 INDONESIA
- 4.11 JAPAN
- 4.12 LAOS
- 4.13 MACAU
- 4.14 MALAYSIA
- 4.15 MALDIVES
- 4.16 MONGOLIA
- 4.17 NEPAL
- 4.18 NORTH KOREA
- 4.19 PAPUA NEW GUINEA
- 4.20 PHILIPPINES
- **4.21 SEYCHELLES**
- **4.22 SINGAPORE**
- 4.23 SOUTH KOREA
- 4.24 SRI LANKA
- 4.25 TAIWAN
- 4.26 THAILAND
- 4.27 TIMOR LESTE, DEMOCRATIC REPUBLIC OF
- 4.28 VIETNAM

5 EUROPE

5.1 EXECUTIVE SUMMARY
5.2 ALBANIA
5.3 ANDORRA
5.4 AUSTRIA
5.5 BELARUS
5.6 BELGIUM
5.7 BOSNIA AND HERZEGOVINA
5.8 BULGARIA
5.9 CROATIA
5.10 CYPRUS
5.11 CZECH REPUBLIC
5.12 DENMARK



+44 20 8123 2220 info@marketpublishers.com

5.13 ESTONIA 5.14 FINLAND 5.15 FRANCE 5.16 GEORGIA 5.17 GERMANY 5.18 GIBRALTAR **5.19 GREECE** 5.20 GUERNSEY 5.21 HUNGARY 5.22 ICELAND 5.23 IRELAND 5.24 ISLE OF MAN **5.25 ITALY** 5.26 JERSEY 5.27 KAZAKHSTAN 5.28 KOSOVO **5.29 LATVIA 5.30 LIECHTENSTEIN** 5.31 LITHUANIA 5.32 LUXEMBOURG 5.33 MACEDONIA 5.34 MALTA 5.35 MOLDOVA 5.36 MONACO 5.37 MONTENEGRO **5.38 NORWAY** 5.39 POLAND 5.40 PORTUGAL 5.41 ROMANIA 5.42 RUSSIA 5.43 SAN MARINO 5.44 SERBIA 5.45 SLOVAKIA 5.46 SLOVENIA **5.47 SPAIN 5.48 SWEDEN** 5.49 SWITZERLAND 5.50 THE FAROE ISLANDS 5.51 THE NETHERLANDS



5.52 THE UNITED KINGDOM 5.53 UKRAINE

6 LATIN AMERICA

6.1 EXECUTIVE SUMMARY6.2 ARGENTINA

- 6.3 BELIZE
- 6.4 BOLIVIA
- 6.5 BRAZIL
- 6.6 CHILE
- 6.7 COLOMBIA
- 6.8 COSTA RICA
- 6.9 ECUADOR
- 6.10 EL SALVADOR
- 6.12 GUATEMALA
- 6.13 GUYANA
- 6.14 HONDURAS
- 6.15 MEXICO
- 6.16 NICARAGUA
- 6.17 PANAMA
- 6.18 PARAGUAY
- 6.19 PERU
- 6.20 SURINAME
- 6.21 THE FALKLAND ISLANDS
- 6.22 URUGUAY
- 6.23 VENEZUELA

7 NORTH AMERICA & THE CARIBBEAN

7.1 EXECUTIVE SUMMARY
7.2 ANGUILLA
7.3 ANTIGUA AND BARBUDA
7.4 ARUBA
7.5 BARBADOS
7.6 BERMUDA
7.7 CANADA
7.8 CUBA
7.9 CURACAO



7.10 DOMINICA 7.11 DOMINICAN REPUBLIC 7.12 GREENLAND 7.13 GRENADA 7.15 HAITI 7.16 JAMAICA 7.18 MONTSERRAT 7.19 PUERTO RICO 7.20 SINT MAARTEN 7.21 ST PIERRE AND MIQUELON 7.22 ST. KITTS AND NEVIS 7.23 ST. LUCIA 7.24 ST. VINCENT AND THE GRENADINES 7.25 THE BAHAMAS 7.26 THE BRITISH VIRGIN ISLANDS 7.27 THE CAYMAN ISLANDS 7.28 THE U.S. VIRGIN ISLANDS 7.29 THE UNITED STATES 7.30 TRINIDAD AND TOBAGO 7.31 TURKS AND CAICOS ISLANDS

8 OCEANIA

8.1 EXECUTIVE SUMMARY 8.2 AMERICAN SAMOA 8.3 AUSTRALIA **8.4 CHRISTMAS ISLAND** 8.6 COOK ISLANDS 8.7 FIJI 8.8 FRENCH POLYNESIA 8.9 GUAM 8.10 KIRIBATI 8.11 MARSHALL ISLANDS 8.12 MICRONESIA FEDERATION 8.13 NAURU 8.14 NEW CALEDONIA 8.15 NEW ZEALAND 8.16 NIUE 8.17 NORFOLK ISLAND





8.18 PALAU
8.19 SOLOMON ISLANDS
8.20 THE NORTHERN MARIANA ISLAND
8.22 TOKELAU
8.23 TONGA
8.24 TUVALU
8.25 VANUATU
8.26 WALLIS AND FUTUNA
8.27 WESTERN SAMOA

9 THE MIDDLE EAST

9.1 EXECUTIVE SUMMARY 9.2 AFGHANISTAN 9.3 ARMENIA 9.4 AZERBAIJAN 9.5 BAHRAIN 9.6 **IRAN** 9.7 IRAQ 9.8 ISRAEL 9.9 JORDAN **9.10 KUWAIT** 9.11 KYRGYZSTAN 9.12 LEBANON 9.13 OMAN 9.14 PAKISTAN 9.15 PALESTINE **9.16 QATAR** 9.17 SAUDI ARABIA 9.18 SYRIAN ARAB REPUBLIC 9.19 TAJIKISTAN 9.20 THE UNITED ARAB EMIRATES **9.21 TURKEY** 9.22 TURKMENISTAN 9.23 UZBEKISTAN **9.24 YEMEN**

10 DISCLAIMERS, WARRANTEES, AND USER AGREEMENT PROVISIONS



10.1 DISCLAIMERS & SAFE HARBOR

10.2 ICON GROUP INTERNATIONAL, INC. USER AGREEMENT PROVISIONS



I would like to order

Product name: The 2021-2026 World Outlook for Coronary Vasodilator Pharmaceuticals Product link: <u>https://marketpublishers.com/r/2300426A6ABEN.html</u>

> Price: US\$ 995.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/2300426A6ABEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970